Automated Assay for Influenza and RSV Cleared
By LabMedica International staff writers Posted on 07 Dec 2014 |
The US Food & Drug Administration (FDA) has cleared an on-demand automated molecular test for rapid, reliable determination of Flu A, Flu B, and differentiation of respiratory syncytial virus (RSV) infection. Redundant targets extend coverage for detection of seasonal and emerging new influenza strains.
The FDA-cleared Xpert Flu/RSV XC cartridge test from Cepheid (Sunnyvale, CA, USA) runs on GeneXpert System, Cepheid’s leading molecular diagnostic platform, with more than 7,500 systems installed worldwide.
Upper respiratory infections are one of the most common reasons for doctor and hospital visits and in the US are the most common illnesses leading to school or work absences. RSV is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age. With Xpert Flu/RSV XC, hospitals and clinicians can be prepared to reliably diagnose and differentiate influenza strains and RSV in real-time. "Influenza strains are notoriously unpredictable and the severity of flu outbreaks can vary widely from season to season," said John Bishop, Cepheid's Chairman and CEO, "Recent media coverage of serious viruses such as Enterovirus D68 and Ebola have raised public awareness, and created a greater need for healthcare workers to deliver timely and accurate test results for flu or RSV infection."
Doctors Donna M. Wolk and Raquel M. Martinez, investigators at Geisinger Health System, were involved in investigational testing of Xpert Flu/RSV XC during Cepheid's product development phase. Their microbiology team is planning a pilot testing program called FluWorks, which aims to allow test results to be immediately delivered to physicians and patients or designated family members via electronic health records, web portal, or text-messaging.
"We are anxious to understand the role that the Xpert Flu/RSV XC test can play in Geisinger's FluWorks program, designed to improve patient care, clinical operations, and laboratory stewardship. Rigorous investigational testing documented the assay's high accuracy and speed," said Dr. Wolk, "This winter, we plan to leverage the test's unique design to quickly test patients presenting with influenza-like illness at emergency departments, out-patient clinics, and in selected urgent-care clinics."
"We employed a novel in silico approach to identify multiple complementary target segments to avoid the effects of seasonal genetic drift and to anticipate emerging novel influenza strains. Though simple to perform, Xpert Flu/RSV XC is a highly multiplexed, state-of-the-art test for fast and accurate detection and differentiation of Flu A, Flu B, and RSV infection," said David Persing, MD, PhD, Cepheid's Chief Medical and Technology Officer, "This test may also become a valuable asset in efforts toward pandemic preparedness, because it was designed from its inception to provide unprecedented coverage of both human and avian influenza strains."
Related Links:
Cepheid
The FDA-cleared Xpert Flu/RSV XC cartridge test from Cepheid (Sunnyvale, CA, USA) runs on GeneXpert System, Cepheid’s leading molecular diagnostic platform, with more than 7,500 systems installed worldwide.
Upper respiratory infections are one of the most common reasons for doctor and hospital visits and in the US are the most common illnesses leading to school or work absences. RSV is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age. With Xpert Flu/RSV XC, hospitals and clinicians can be prepared to reliably diagnose and differentiate influenza strains and RSV in real-time. "Influenza strains are notoriously unpredictable and the severity of flu outbreaks can vary widely from season to season," said John Bishop, Cepheid's Chairman and CEO, "Recent media coverage of serious viruses such as Enterovirus D68 and Ebola have raised public awareness, and created a greater need for healthcare workers to deliver timely and accurate test results for flu or RSV infection."
Doctors Donna M. Wolk and Raquel M. Martinez, investigators at Geisinger Health System, were involved in investigational testing of Xpert Flu/RSV XC during Cepheid's product development phase. Their microbiology team is planning a pilot testing program called FluWorks, which aims to allow test results to be immediately delivered to physicians and patients or designated family members via electronic health records, web portal, or text-messaging.
"We are anxious to understand the role that the Xpert Flu/RSV XC test can play in Geisinger's FluWorks program, designed to improve patient care, clinical operations, and laboratory stewardship. Rigorous investigational testing documented the assay's high accuracy and speed," said Dr. Wolk, "This winter, we plan to leverage the test's unique design to quickly test patients presenting with influenza-like illness at emergency departments, out-patient clinics, and in selected urgent-care clinics."
"We employed a novel in silico approach to identify multiple complementary target segments to avoid the effects of seasonal genetic drift and to anticipate emerging novel influenza strains. Though simple to perform, Xpert Flu/RSV XC is a highly multiplexed, state-of-the-art test for fast and accurate detection and differentiation of Flu A, Flu B, and RSV infection," said David Persing, MD, PhD, Cepheid's Chief Medical and Technology Officer, "This test may also become a valuable asset in efforts toward pandemic preparedness, because it was designed from its inception to provide unprecedented coverage of both human and avian influenza strains."
Related Links:
Cepheid
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia